Medindia LOGIN REGISTER
Medindia

Transgene Biotek Gets US Patent for Developing Novel Drug to Treat Liver Cancer

by Bidita Debnath on Jul 7 2015 5:30 PM

Transgene Biotek Gets US Patent for Developing Novel Drug to Treat Liver Cancer
Biotechnology firm Transgene Biotek has received patent in the US for its novel drug to be developed for treatment of Hepato-cellular cancer (HCC) the most common liver cancer.
"This granting of a USA patent is a significant step in moving ahead with the development of this novel drug," Transgene Biotek said in a filing to the BSE (Bombay Stock Exchange).

The company’s novel molecule miRNA 101 for therapy against liver cancer has been allowed for issuance of a USA patent after the prosecution on merits have been closed, it added.

HCC is the most common primary liver cancer, accounting to roughly 90% of this class of malignancy, with poor prognosis due to its ability to rapidly spread, Transgene Biotek said.

The company’s current product portfolio covers segments such as oncology, auto-immunity, drug delivery and bio-generics.

Shares of Transgene Biotek closed 4.90% up at Rs 2.57 per scrip on the BSE.

Source-Medindia


Advertisement